



Datasheet for ABIN678578  
**anti-FLT4 antibody (AA 901-1000)**



[Go to Product page](#)

3 Images

3 Publications

### Overview

Quantity:	100 µL
Target:	FLT4
Binding Specificity:	AA 901-1000
Reactivity:	Human, Mouse, Cow
Host:	Rabbit
Clonality:	Polyclonal
Conjugate:	This FLT4 antibody is un-conjugated
Application:	ELISA, Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunocytochemistry (ICC)

### Product Details

Immunogen:	KLH conjugated synthetic peptide derived from Mouse VEGFR-3
Isotype:	IgG
Cross-Reactivity:	Cow, Human, Mouse
Predicted Reactivity:	Rat
Purification:	Purified by Protein A.

### Target Details

Target:	FLT4
---------	------

## Target Details

---

Alternative Name: [VEGFR3 \(FLT4 Products\)](#)

Background: Synonyms: PCL, FLT41, LMPH1A, VEGFR3, Vascular endothelial growth factor receptor 3, VEGFR-3, Fms-like tyrosine kinase 4, FLT-4, Tyrosine-protein kinase receptor FLT4, FLT4  
Background: Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFC and VEGFD, and plays an essential role in adult lymphangiogenesis and in the development of the vascular network and the cardiovascular system during embryonic development. Promotes proliferation, survival and migration of endothelial cells, and regulates angiogenic sprouting. Signaling by activated FLT4 leads to enhanced production of VEGFC, and to a lesser degree VEGFA, thereby creating a positive feedback loop that enhances FLT4 signaling. Modulates KDR signaling by forming heterodimers. The secreted isoform 3 may function as a decoy receptor for VEGFC and/or VEGFD and play an important role as a negative regulator of VEGFC-mediated lymphangiogenesis and angiogenesis. Binding of vascular growth factors to isoform 1 or isoform 2 leads to the activation of several signaling cascades, isoform 2 seems to be less efficient in signal transduction, because it has a truncated C-terminus and therefore lacks several phosphorylation sites. Mediates activation of the MAPK1/ERK2, MAPK3/ERK1 signaling pathway, of MAPK8 and the JUN signaling pathway, and of the AKT1 signaling pathway. Phosphorylates SHC1. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase. Promotes phosphorylation of MAPK8 at 'Thr-183' and 'Tyr-185', and of AKT1 at 'Ser-473'.

---

Gene ID: 2324

---

UniProt: [P35916](#)

---

Pathways: [RTK Signaling, Signaling Events mediated by VEGFR1 and VEGFR2, VEGF Signaling](#)

## Application Details

---

Application Notes: WB 1:300-5000  
ELISA 1:500-1000  
FCM 1:20-100  
IHC-P 1:200-400  
IHC-F 1:100-500  
IF(IHC-P) 1:50-200  
IF(IHC-F) 1:50-200  
IF(ICC) 1:50-200  
ICC 1:100-500

---

Restrictions: For Research Use only

## Handling


---

Format:	Liquid
Concentration:	1 µg/µL
Buffer:	0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
Preservative:	ProClin
Precaution of Use:	This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
Storage:	4 °C,-20 °C
Storage Comment:	Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
Expiry Date:	12 months

## Publications


---

Product cited in:	<p>Wang, Wang, Li, Wu, Sun, Chen, Feng, Chen, Cai, Xu, He: "CXCL1 from tumor-associated lymphatic endothelial cells drives gastric cancer cell into lymphatic system via activating integrin β1/FAK/AKT signaling." in: <b>Cancer letters</b>, Vol. 385, pp. 28-38, (2016) (<a href="#">PubMed</a>).</p> <p>Zhuo, Jia, Song, Lu, Ding, Wang, Song, Fu, Luo: "The CXCL12-CXCR4 chemokine pathway: a novel axis regulates lymphangiogenesis." in: <b>Clinical cancer research : an official journal of the American Association for Cancer Research</b>, Vol. 18, Issue 19, pp. 5387-98, (2012) (<a href="#">PubMed</a>).</p> <p>Wang, Zhou, Lin, Wang, Lin, Li: "RhGH attenuates ischemia injury of intrahepatic bile ducts relating to liver transplantation." in: <b>The Journal of surgical research</b>, Vol. 171, Issue 1, pp. 300-10, (2011) (<a href="#">PubMed</a>).</p>
-------------------	---




### Immunohistochemistry

**Image 1.** Formalin-fixed and paraffin embedded human gastric cancer labeled with Anti-VEGFR3 Polyclonal Antibody, Unconjugated (ABIN678578) at 1:200 followed by conjugation to the secondary antibody and DAB staining



### Immunohistochemistry

**Image 2.** Formalin-fixed and paraffin embedded human gastric cancer labeled with Anti-VEGFR3 Polyclonal Antibody, unconjugated (ABIN678578) at 1: 200 followed by incubation with conjugated secondary antibody and DAB staining



### Flow Cytometry

**Image 3.** A549 cells probed with VEGFR3 Polyclonal Antibody, Unconjugated at 1:100 for 30 minutes followed by incubation with a conjugated secondary (PE conjugated) (green) for 30 minutes compared to control cells (blue), secondary only (light blue) and isotype control (orange).